相关实验视频
Updated: May 6, 2026

09:16
Assessment of Kidney Function in Mouse Models of Glomerular Disease
Published on: June 30, 2018
17.6K
在增殖性淋巴结膜炎和狼性炎模型中抑制PIK3CA
Junna Yamaguchi1,2,3, Pierre Isnard1,3,4, Noémie Robil5
1Université Paris Cité, Paris, France.
The Journal of clinical investigation
|June 6, 2024
概括
一个PIK3CA突变通过影响脏细胞驱动增殖性淋巴结膜炎. PI3Kα抑制剂alpelisib通过向脏和免疫细胞来治疗病,显示出有前景.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 增殖性淋巴结膜炎是一种严重的脏疾病,治疗选择有限.
- 细胞中的体质PIK3CA功能增益突变与疾病病原发生有关.
研究的目的:
- 为了研究PI3K途径在增殖性淋巴结膜炎中的作用.
- 评估PI3Kα抑制剂alpelisib在病模型中的治疗潜力.
主要方法:
- 基因工程小鼠模型的基因工程.
- 单细胞RNA测序的一个细胞.
- 空间转录组学 空间转录组学
- 用alpelisibib进行药理抑制.
主要成果:
- PI3Kα通路的激活促进了皮细胞的增殖,分离和炎症.
- 在小鼠模型中,阿尔佩利西布治疗改善了功能和球损伤.
- 在狼性炎模型中,PI3Kα抑制调节的淋巴细胞群和减少的前炎性标志物,模仿PI3Kδ抑制效应而不会影响正常的淋巴细胞功能.
结论:
- PI3Kα在增殖性淋巴结膜炎的发展中起着至关重要的作用.
- 阿尔佩利西布通过向细胞和免疫细胞来证明治疗疗效.
更多相关视频
09:43Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
2.9K
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
397
相关概念视频
The JAK-STAT Signaling Pathway
10.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.3K
PI3K/mTOR/AKT Signaling Pathway
5.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.2K